We report for the first time that CD47-MET fusion NSCLC is primarily resistant to immunotherapy, which may be associated with MET activation-induced immunosuppressive microenvironments while positive PD-L1 expression is not a predictor of immunotherapeutic efficacy in this type of NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.